Fundraising USA TriGemX Bio Raises $94 Million to Advance Phase 3 Migraine Drug Elismetrep Bipsiq October 1, 2026 0 TriGemX Bio, formerly Kallyope, closed a $94 million financing co-led by The Column Group,...Read More